search
Back to results

Pilot of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor HCT

Primary Purpose

AML, ALL, Undifferentiated Leukemia

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Abatacept
Sponsored by
Boston Children's Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for AML focused on measuring cancer, leukemia, transplant, bone marrow

Eligibility Criteria

12 Years - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Patients with AML, with or without a history of myelodysplastic syndrome in one of the following categories.

    (a) Patients in first complete remission with high-risk features

  2. Patients with ALL, in either of the following categories:

    1. In 2nd or greater complete remission (complete remission is defined as > 5% blasts in marrow)
    2. Delayed 1st CR-Failure to achieve complete remission after a single round of induction therapy
  3. Patients with undifferentiated or biphenotypic leukemia in 1st or greater complete remission.
  4. Patients with Myelodysplastic Syndrome(s) with an IPSS score of >1.5 and <10% blasts in the bone marrow at the time of transplant. These conditions will include:

    1. Refractory anemia
    2. Refractory anemia with ringed sideroblasts
    3. Refractory cytopenia with multilineage dysplasia
    4. Refractory cytopenia with multilineage dysplasia and ringed sideroblasts
    5. Refractory anemia with excess blasts-1 (5-10% blasts)
    6. Refractory anemia with excess blasts-2 (10-20% blasts)
    7. Myelodysplastic syndrome, unclassified
    8. MDS associated with isolated del (5q)
    9. Patients diagnosed with AML in CR1 after an initial diagnosis of MDS.
  5. Age 12 years or older.
  6. No prior allogeneic transplant
  7. Karnofsky performance score or Lansky Play-Performance of at least 80.
  8. Signed informed consent for adults and for minors the provision of pediatric assent and parental permission.

Exclusion Criteria:

  1. Age <12 years old.
  2. Patients requiring >2 courses of induction chemotherapy to achieve remission status.
  3. HIV infection
  4. Tuberculosis Infection
  5. Chronic Obstructive Pulmonary Disease
  6. Pregnancy (positive serum b-HCG) or breastfeeding
  7. Creatinine clearance or nuclear medicine GFR of < 50 mL/min
  8. Cardiac ejection fraction < 50%
  9. bilirubin > 2 × upper limit of normal or ALT > 4 × upper limit of normal or unresolved veno-occlusive disease.
  10. Pulmonary disease with FVC, FEV1 or DLCO parameters <45% predicted (corrected for hemoglobin) or O2 saturation <92% on room air.
  11. Karnofsky performance score or Lansky Play-Performance Scale <80
  12. Uncontrolled viral, bacterial, or fungal infection at the time of study enrollment
  13. Availability of a willing and fully MHC-matched related donor.
  14. Positive cytotoxic recipient-donor cross-match or positive HLA antibody screen against donor-disparate antigens.
  15. Any active infection.
  16. Unable to obtain informed consent.

Sites / Locations

  • Boston Children's Hospital

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Abatacept

Arm Description

Participants will receive one of two standard myeloablative conditioning regimens for their stem cell transplant, and will receive an aGvHD prophylaxis regimen including cyclosporine, methotrexate, and abatacept.

Outcomes

Primary Outcome Measures

Percentage of Participants With Grade III-IV Acute GVHD by Day 100.
Grade III-IV Acute GVHD by Day 100. The incidence of Gr III-IV acute GVHD was measured by the modified Glucksburg scale.

Secondary Outcome Measures

Percentage of Participants With Grades III-IV Acute GVHD at 2 Years
The rates of Grades III-IV acute GVHD were measured at 2 years according to standard Glucksberg criteria, which was 10%.
Hematologic and Immunologic Reconstitution
Flow cytometric analysis of CD4 t-cell t-cell reconstitution was performed at day +100 post-transplant.
Protective Immunity
Percent of CMV virus binding CD8+ t-cells at day +365 post-transplant

Full Information

First Posted
November 11, 2009
Last Updated
October 31, 2019
Sponsor
Boston Children's Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT01012492
Brief Title
Pilot of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor HCT
Official Title
Safety and Tolerability Trial of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor Hematopoietic Stem Cell Transplant
Study Type
Interventional

2. Study Status

Record Verification Date
October 2019
Overall Recruitment Status
Completed
Study Start Date
November 2009 (undefined)
Primary Completion Date
November 2012 (Actual)
Study Completion Date
January 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Boston Children's Hospital

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The primary objective of the study is to determine the safety and tolerability when adding abatacept to acute Graft versus Host Disease in transplants for malignant diseases using unrelated donor bone marrow or peripheral blood stem cell grafts.
Detailed Description
Acute Graft versus Host Disease (aGvHD) is the most deadly complication facing children who have allogeneic hematopoietic stem cell transplant (HSCT). aGvHD occurs, in large part, because the T cells in the bone marrow graft do not "accept" the presence of the transplant recipient's cells, and mount a severe, debilitating, and often deadly attack against the recipient, striking the skin, the liver, and the gastrointestinal track, most prominently. For patients receiving bone marrow from an unrelated donor, the rate of aGvHD can reach as high as 80%, with up to half of patients dying from this complication. These serious outcomes occur despite our best efforts at aGvHD prevention. Given the lack of success in preventing aGvHD with current therapies, novel therapies to prevent this disease are desperately needed. In this study, we plan to test a novel drug to prevent aGvHD. This drug, known as abatacept, specifically blocks the activation pathway critical to T cell function known as "T cell costimulation." In particular, it blocks the CD28-mediated costimulation pathway that is critical for optimal T cell activation and proliferation. My research group has done extensive pre-clinical work with this compound. Our work has demonstrated its efficacy in inducing immune tolerance after transplantation in both mouse models and primate models. In addition, patient trials have demonstrated that blocking CD28-directed T cell costimulation can prevent T cell-mediated diseases, including rheumatoid arthritis and psoriasis, and can improve solid organ transplant acceptance. Abatacept is currently FDA approved for use in rheumatoid arthritis. Given this drug's safety and efficacy profile, we have been granted an IND-exemption from the FDA for the inclusion of abatacept in a GvHD-prevention strategy. This is a safety and tolerability study of the addition of abatacept to a GvHD-prophylaxis regimen. Thus, the primary objective of the study is to determine the safety and tolerability of the addition of abatacept to aGvHD prophylaxis in transplants for malignant hematologic disease using unrelated donor bone marrow or peripheral blood stem cell grafts. Three secondary objectives will also be addressed: We will estimate the incidence and severity of aGvHD in patients receiving the abatacept-based protocol. We will determine the immune phenotype of donor cells in patients receiving abatacept. We will determine the ability of donor T-cells in patients receiving abatacept to respond to both polyclonal and recipient-specific immune stimulation. These secondary objectives will allow us to determine the impact of abatacept-containing GvHD prevention on both T cell alloreactivity and on T cell-mediated protective immunity. This study is for patients older than 12 who have been diagnosed with high-risk leukemia and for whom an unrelated bone marrow transplant is planned. We plan to enroll 10 patients on the study, over a 1-year period from the opening of the trial. Of these ten patients, at least five will be pediatric patients; the other five may be from adult patients taken care of by Winship Cancer Center physicians. All clinical study coordination and biologic studies will be performed by CHOA personnel. Participants will receive one of two standard myeloablative conditioning regimens for their stem cell transplant, and will receive an aGvHD prophylaxis regimen including cyclosporine, methotrexate, and abatacept. They will have immunologic analysis for 1 year after transplant and clinical analysis for 3 years after transplant.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
AML, ALL, Undifferentiated Leukemia, Biphenotypic Leukemia, Refractory Anemia, Refractory Anemia With Ringed Sideroblasts, Refractory Cytopenia With Multilineage Dysplasia, Ref. Cytopenia w Multilineage Dysplasia & Ringed Sideroblasts, Refractory Anemia With Excess Blasts-1 (5-10% Blasts), Refractory Anemia With Excess Blasts-2 (10-20% Blasts), Myelodysplastic Syndrome, Unclassified, MDS Associated With Isolated Del (5q)
Keywords
cancer, leukemia, transplant, bone marrow

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
11 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Abatacept
Arm Type
Experimental
Arm Description
Participants will receive one of two standard myeloablative conditioning regimens for their stem cell transplant, and will receive an aGvHD prophylaxis regimen including cyclosporine, methotrexate, and abatacept.
Intervention Type
Drug
Intervention Name(s)
Abatacept
Other Intervention Name(s)
orencia
Intervention Description
Participants will receive one of two standard myeloablative conditioning regimens for their stem cell transplant, and will receive an aGvHD prophylaxis regimen including cyclosporine, methotrexate, and abatacept.
Primary Outcome Measure Information:
Title
Percentage of Participants With Grade III-IV Acute GVHD by Day 100.
Description
Grade III-IV Acute GVHD by Day 100. The incidence of Gr III-IV acute GVHD was measured by the modified Glucksburg scale.
Time Frame
Day 100 post-transplant
Secondary Outcome Measure Information:
Title
Percentage of Participants With Grades III-IV Acute GVHD at 2 Years
Description
The rates of Grades III-IV acute GVHD were measured at 2 years according to standard Glucksberg criteria, which was 10%.
Time Frame
2 years after transplant
Title
Hematologic and Immunologic Reconstitution
Description
Flow cytometric analysis of CD4 t-cell t-cell reconstitution was performed at day +100 post-transplant.
Time Frame
Day +100 post-transplant
Title
Protective Immunity
Description
Percent of CMV virus binding CD8+ t-cells at day +365 post-transplant
Time Frame
Day +365 post-transplant

10. Eligibility

Sex
All
Minimum Age & Unit of Time
12 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients with AML, with or without a history of myelodysplastic syndrome in one of the following categories. (a) Patients in first complete remission with high-risk features Patients with ALL, in either of the following categories: In 2nd or greater complete remission (complete remission is defined as > 5% blasts in marrow) Delayed 1st CR-Failure to achieve complete remission after a single round of induction therapy Patients with undifferentiated or biphenotypic leukemia in 1st or greater complete remission. Patients with Myelodysplastic Syndrome(s) with an IPSS score of >1.5 and <10% blasts in the bone marrow at the time of transplant. These conditions will include: Refractory anemia Refractory anemia with ringed sideroblasts Refractory cytopenia with multilineage dysplasia Refractory cytopenia with multilineage dysplasia and ringed sideroblasts Refractory anemia with excess blasts-1 (5-10% blasts) Refractory anemia with excess blasts-2 (10-20% blasts) Myelodysplastic syndrome, unclassified MDS associated with isolated del (5q) Patients diagnosed with AML in CR1 after an initial diagnosis of MDS. Age 12 years or older. No prior allogeneic transplant Karnofsky performance score or Lansky Play-Performance of at least 80. Signed informed consent for adults and for minors the provision of pediatric assent and parental permission. Exclusion Criteria: Age <12 years old. Patients requiring >2 courses of induction chemotherapy to achieve remission status. HIV infection Tuberculosis Infection Chronic Obstructive Pulmonary Disease Pregnancy (positive serum b-HCG) or breastfeeding Creatinine clearance or nuclear medicine GFR of < 50 mL/min Cardiac ejection fraction < 50% bilirubin > 2 × upper limit of normal or ALT > 4 × upper limit of normal or unresolved veno-occlusive disease. Pulmonary disease with FVC, FEV1 or DLCO parameters <45% predicted (corrected for hemoglobin) or O2 saturation <92% on room air. Karnofsky performance score or Lansky Play-Performance Scale <80 Uncontrolled viral, bacterial, or fungal infection at the time of study enrollment Availability of a willing and fully MHC-matched related donor. Positive cytotoxic recipient-donor cross-match or positive HLA antibody screen against donor-disparate antigens. Any active infection. Unable to obtain informed consent.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Leslie Kean, MD, PhD
Organizational Affiliation
Boston Children's Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Boston Children's Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02115
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
24047754
Citation
Koura DT, Horan JT, Langston AA, Qayed M, Mehta A, Khoury HJ, Harvey RD, Suessmuth Y, Couture C, Carr J, Grizzle A, Johnson HR, Cheeseman JA, Conger JA, Robertson J, Stempora L, Johnson BE, Garrett A, Kirk AD, Larsen CP, Waller EK, Kean LS. In vivo T cell costimulation blockade with abatacept for acute graft-versus-host disease prevention: a first-in-disease trial. Biol Blood Marrow Transplant. 2013 Nov;19(11):1638-49. doi: 10.1016/j.bbmt.2013.09.003. Epub 2013 Sep 15.
Results Reference
result
PubMed Identifier
25852054
Citation
Suessmuth Y, Mukherjee R, Watkins B, Koura DT, Finstermeier K, Desmarais C, Stempora L, Horan JT, Langston A, Qayed M, Khoury HJ, Grizzle A, Cheeseman JA, Conger JA, Robertson J, Garrett A, Kirk AD, Waller EK, Blazar BR, Mehta AK, Robins HS, Kean LS. CMV reactivation drives posttransplant T-cell reconstitution and results in defects in the underlying TCRbeta repertoire. Blood. 2015 Jun 18;125(25):3835-50. doi: 10.1182/blood-2015-03-631853. Epub 2015 Apr 7.
Results Reference
result

Learn more about this trial

Pilot of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor HCT

We'll reach out to this number within 24 hrs